Core Insights - The World Health Organization (WHO) warns about the rapid adoption of artificial intelligence (AI) in healthcare, highlighting significant gaps in legal and ethical safeguards [1][2] Group 1: AI Adoption in Healthcare - Nearly all countries recognize the potential of AI in diagnosis, disease monitoring, and personalized medicine [1] - 32 out of 50 surveyed European countries have adopted AI-assisted diagnostics, and half have introduced chatbots for patient support [1] - Over half of the countries have identified priority application areas for AI in healthcare, driven by the need to improve patient care quality, alleviate workforce pressure, and enhance efficiency and productivity [1] Group 2: Challenges and Barriers - 86% of the surveyed countries view "legal uncertainty" as the primary barrier to AI application in healthcare, while 78% cite "insufficient funding" as a major issue [1] - Only 25% of the countries provide dedicated funding for healthcare AI, and less than 8% have established "responsibility standards" for AI-related errors or harm [1] Group 3: Recommendations for Policy and Strategy - The report emphasizes the need for countries to develop national strategies for healthcare AI that align with public health goals [2] - It calls for investments in capacity building, strengthening legal and ethical safeguards, and improving cross-border data governance [2]

世卫组织对医疗人工智能快速扩张发出警告 中新网北京11月20日电 世界卫生组织(以下简称世卫组织)在其最新报告中对医疗领域大规模采用人工智 能发出警告，指出相关法律、伦理保障等严重滞后。 据联合国新闻官网19日消息，世卫组织基于欧洲区域50国的情况反馈发布《健康领域的人工智能：欧洲 区域准备现状》报告，首次系统呈现人工智能在医疗体系中的应用、监管与风险现状。 报告指出，几乎所有国家都意识到人工智能在诊疗、疾病监测和个性化医疗中的潜力。人工智能已在诊 断、流程优化和提升医患沟通方面发挥重要作用，但同时，责任划分模糊、数据安全不足和法律框架缺 失等问题日益突出。 报告显示，调研涉及的欧洲区域50个国家中，32个国家已采用人工智能辅助诊断，半数国家引入聊天机 器人用于患者支持，超过半数国家明确了医疗领域人工智能的优先应用方向。各国推动医疗人工智能的 主要动机包括，提升患者护理质量、缓解医疗系统人力压力以及提高效率和生产力。 报告同时指出，调研涉及的欧洲国家中，86%认为"法律不确定性"是医疗人工智能应用的首要障碍， 78%将"资金不足"视为主要问题。仅有25%的国家为医疗人工智能提供专项资金，不足8%的国家制定 了 ...

证券之星消息，根据天眼查APP于11月10日公布的信息整理，福鑫数科（杭州）人工智能有限公司Pre- A轮融资，融资额5000万人民币，参与投资的机构包括远毅资本，长岭资本。 | 公布日 | 投资方 | 交易金额 | 融资轮次 | | --- | --- | --- | --- | | 2025-11-10 | 近数各本 长岭盗本 | 5000万人民币 | Pre-A轮 | | 2023-03-13 | 长岭资本 | 5000万人民币 | 天使轮 | 数据来源：天眼查APP 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 福鑫数科（杭州）人工智能有限公司是一家专注于医疗人工智能技术研发与应用的企业，成立于2015年 4月8日，总部位于浙江省杭州市拱墅区。公司以"FusionAi"系列医疗人工智能产品为核心，推动医院从 信息化向智能化转型。 ...

Domestic Investment - Zhizili Technology completed seed round financing of several million yuan, led by Cloud Angel Fund, focusing on a six-dimensional force sensing solution using self-developed machine learning algorithms and fiber grating sensing technology [1] - Xiyuan Anjian announced over 200 million yuan A round financing, led by Beijing Pharmaceutical Health Industry Investment Fund, to support the key III phase clinical research of its CGRP small molecule drug BR005 [2] - Fuxin Digital completed 50 million yuan Pre-A round financing, led by Yuan Yi Capital, to enhance its AI medical solutions and expand its team [3][4] - Jiayu Medical secured several million yuan angel round financing, led by Guokai Investment, to accelerate the registration and clinical promotion of its handheld magnetic particle imaging system [5] - Fengjia Technology and Xingwang Xintong received approval for their listings on the New Third Board, focusing on chip design and integrated communication solutions respectively [6][7] - Zhizhi Chip completed seed round financing of tens of millions of yuan, focusing on high-performance operator discovery and optimization [8] - Yuntu Zhixing raised tens of millions of dollars in angel round financing, focusing on geographic information and spatial intelligence computing [9] - Yuying Trade completed 8 million yuan angel round financing, focusing on software development and brand customization [10] - Nuowan Microelectronics completed nearly 100 million yuan angel round financing, focusing on optical interconnection chips [11] - Henan Hippo Technology completed 26 million yuan angel round financing, focusing on short video social e-commerce [12] - Anxin Medical completed a significant angel round financing to enhance its gynecological diagnostic tools [13] Foreign Investment - 1Mind AI raised $30 million in A round financing, focusing on AI sales service tools [14] - Scribe completed $75 million in C round financing, with a post-financing valuation of $1.3 billion, focusing on workflow management software [15] - Onchilles Pharma raised $25 million in A1 round financing, focusing on broad-spectrum cancer treatment candidates [16] - Majestic Labs secured $100 million in A round financing, focusing on AI infrastructure for high-memory AI servers [17] - Iambic Therapeutics received $100 million in strategic investment, focusing on AI-driven medical platforms [18] - Gamma completed $68 million in B round financing, achieving a valuation of $2.1 billion, focusing on AI-generated presentations [19] IPO Queue - Real Bio submitted an IPO application, focusing on innovative drug development for antiviral and oncology treatments [20] - Mindray Medical submitted an IPO application, focusing on medical device development across multiple fields [21] - Zhongding Intelligent submitted an IPO application, focusing on customized solutions for various industries [22]

（编辑 楚丽君） 证券日报网讯 11月11日晚间，九州通发布公告称，为进一步促进旗下产业孵化器发展，加大在创新医 疗器械、医疗人工智能等新兴产业的战略布局，九州通医药集团股份有限公司（以下简称"公司"）控股 孙公司北京九州众创科技孵化器有限公司作为有限合伙人认缴出资1，000万元参与设立武汉市楚昌通达 产业投资基金合伙企业（有限合伙）（以下简称"产业基金"），占产业基金认缴出资总额的7.14%。 2025年11月10日，公司收到基金管理人通知，该产业基金已在中国证券投资基金业协会完成备案手续， 并取得了《私募投资基金备案证明》。 ...

（文章来源：每日经济新闻） 每经AI快讯，11月11日，据光源资本官微消息，福鑫数科（杭州）人工智能有限公司（原湖北福鑫科创 信息技术有限公司）已完成5000万元人民币Pre-A轮融资。本轮融资由远毅资本领投、老股东长岭资本 超额追投，光源资本担任独家财务顾问。融资资金将主要用于FusionAi系列医疗人工智能产品的技术迭 代、全国规模化落地和渠道建设以及人才团队的进一步扩充。 ...

Core Viewpoint - The rapid advancement of artificial intelligence (AI) technology is accelerating the development of medical AI to assist doctors and undertake some of their technical labor, raising concerns about the safety and effectiveness of its application [1][2]. Group 1: Establishment of Evaluation Center - The Beijing Municipal Health Commission has established a Medical AI Application Evaluation Center to create a regulatory framework and standards for evaluating medical AI [1][2]. - The center aims to verify the clinical decision-making capabilities and effectiveness of medical AI, ensuring a safety baseline for its application [1]. Group 2: Evaluation Standards and Methodology - The evaluation of medical AI should be as rigorous as that of human doctors, focusing on multiple dimensions such as safety, professionalism, and practicality [2]. - A multi-dimensional assessment framework has been developed, consisting of six core evaluation dimensions: medical compliance and ethics, evidence-based medicine and knowledge, general auxiliary capabilities, specialty diagnosis and treatment quality control, adaptability of treatment processes, and accuracy of treatment decisions, encompassing over 70 specific evaluation tasks [2][3]. - The evaluation center collaborates with key hospitals, research institutions, and authoritative expert teams to construct a high-quality evaluation dataset using clinical cases and the latest clinical guidelines [2]. Group 3: Innovative Evaluation Mechanism - The evaluation system automatically matches tasks based on application types and generates evaluation reports, which are then reviewed by clinical experts [3]. - An AI-based scoring mechanism has been introduced to quantify scores based on diagnostic reasoning, logic, and results, ensuring objective and scientifically credible evaluation outcomes [3]. - The center plans to expand its evaluation services to cover various medical fields, including internal medicine, surgery, and pediatrics, to support the healthy development of the medical AI industry [3].

Core Viewpoint - The rapid advancement of artificial intelligence (AI) technology is driving the development of medical AI to assist doctors and take on some of their technical tasks, raising concerns about the safe and effective application of medical AI [1][3] Group 1: Establishment of Evaluation Center - The Beijing Municipal Health Commission has established a Medical AI Application Evaluation Center to create a regulatory framework and standards for medical AI evaluation [1][3] - The center aims to validate the clinical decision-making capabilities and effectiveness of medical AI, ensuring safety in its application [1][3] Group 2: Evaluation Criteria - Medical AI applications will be evaluated similarly to doctors, focusing on multiple dimensions such as safety, professionalism, and practicality [3] - A multi-dimensional assessment standard has been developed, consisting of six core evaluation dimensions: medical compliance and ethics, evidence-based medicine and knowledge, general auxiliary capabilities, specialty diagnosis and treatment quality control, adaptability of diagnosis and treatment processes, and accuracy of diagnostic decisions, encompassing over 70 specific evaluation tasks [3][4] Group 3: Data and Methodology - The evaluation center collaborates with key hospitals, research institutions, and authoritative expert teams to construct a high-quality evaluation dataset using clinical cases and authoritative medical guidelines [3][4] - An innovative AI-based scoring mechanism has been introduced to ensure objective and scientific evaluation results, focusing on reasoning logic and diagnostic thought processes rather than just final outcomes [4] Group 4: Future Plans - The evaluation center plans to expand its evaluation services to cover various medical fields, including internal medicine, surgery, and pediatrics, to support the healthy development of the medical AI industry and better meet public health needs [5]

Core Insights - The rapid advancement of artificial intelligence technology is propelling medical AI towards assisting doctors and taking on some of their technical tasks [1] - Ensuring the standardized, safe, and effective application of medical AI has become a significant concern for the public and the industry [1] Group 1 - The Beijing Municipal Health Commission has established a Medical Artificial Intelligence Application Evaluation Center [1] - The purpose of the evaluation center is to create a system and standard for the evaluation of medical AI applications [1] - The center will leverage high-level hospitals, expert teams, and quality medical data in Beijing to validate the clinical decision-making capabilities and effectiveness of medical AI [1]

央广网北京11月7日消息（总台中国之声记者白杰戈）据中央广播电视总台中国之声报道，北京市 卫生健康委今天（7日）发布《关于开展医疗领域人工智能应用评测工作的通知》（以下简称《通 知》），正式向各企业、研究机构提供评测服务。 "评测结果的科学性"。考试中如果只靠专家凭经验打分，可能会有主观偏差；只靠选择题的准确率 或者得分点的计分，又会漏掉对思考过程的评价。因此，对医疗人工智能应用的评测，不能只看答案， 还要对它的思考和答题过程进行评价，防止"蒙"对了结果，逻辑却错了。 针对上述这几个医疗领域人工智能应用评测的重点难点问题，北京市卫生健康委委托北京市卫生健 康大数据与政策研究中心，配合医疗领域国家人工智能应用中试基地建设，联合全国重点医院与顶尖专 家团队，拿出破题方案，打造了北京医疗人工智能应用评测中心。 评测引入"裁判模型"判卷考察逻辑水平 北京市卫生健康委表示，医疗AI的评测是一项高度专业性的工作，必须依托深厚的医学知识与临 床经验开展，需要顶尖医疗专家的深度参与，需要汇聚医疗行业领域内最前沿的智慧，确保评测工作既 科学严谨又切合临床实际。为此，北京市卫生健康委在国家基地建设中专门设立了医疗人工智能应用评 ...